

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all previously submitted listings of claims:

1-29. **(Cancelled)**

30. **(Currently amended)** A method of treating an oncological disease comprising stimulating a multi-epitopic immune response to a tumor-associated antigen comprising

administering to a host a complex formed from a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein the tumor-associated antigen is ~~a—self-antigen~~CA125, and wherein the administration of the complex induces host antibodies reactive with at least one other epitope of the tumor-associated antigen.

31-70. **(Cancelled)**

71. **(Previously presented)** The method of claim 30, wherein the antibody is selected from the group consisting of a monoclonal antibody, a single chain antibody, a humanized antibody, and a chimeric antibody.

72-75. **(Cancelled)**

76. **(Previously presented)** The method of claim 30, wherein the host is a human.

77-84. **(Cancelled)**

85. **(Currently amended)** A composition suitable for administration to a host for altering immunogenicity of a tumor-associated antigen comprising a complex of a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that specifically binds to an epitope of the antigen, wherein said tumor-associated antigen is ~~a—self-antigen~~CA125, and wherein administration of the composition to a host results in a multi-epitopic immune response including production of antibodies reactive with at least one other epitope associated with the tumor-associated antigen.

86. **(Previously presented)** The composition of claim 85, wherein the antibody is selected from the group consisting a monoclonal antibody, a single chain antibody, a humanized antibody, and a chimeric antibody.

87. **(Previously presented)** The composition of claim 85, wherein the antibody is a monoclonal antibody.

88. **(Previously presented)** The composition of claim 87, wherein the monoclonal antibody is produced by the hybridoma having ATCC deposit number PTA-1883.

89-95. **(Cancelled)**

96. **(Previously presented)** The composition of claim 85, wherein the host is a human.

97. **(Cancelled)**

98. **(Previously presented)** The method of claim 30, wherein the antibody is a non-human antibody.

99. **(Previously presented)** The method of claim 30, wherein the complex is administered with an adjuvant.

100. **(Previously presented)** The method of claim 30, wherein the antibody or antigen binding fragment thereof of the complex is formulated at a dose of from about 0.1 μg to about 2 mg per kilogram of body weight of the host.

101.-102. **(Cancelled)**

103. **(Currently amended)** The method of claim 30, wherein the soluble complex induces cytotoxic T cells reactive with ~~at least one other epitope of~~ the antigen.

104. **(Currently amended)** A method of treating an oncological disease comprising stimulating a multi-epitopic immune response to a tumor-associated antigen comprising administering to a host a complex consisting essentially of a soluble tumor-associated antigen and an antibody or antigen

binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein said tumor-associated antigen is ~~a self-antigen~~CA125, and wherein the administration of the complex induces host antibodies and cytotoxic T cells reactive with ~~at least one other epitope of~~ the tumor-associated antigen.

105. **(Currently amended)** A method of treating an oncological disease comprising stimulating a multi-epitopic immune response to a tumor-associated antigen comprising administering to a host a complex consisting essentially of a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein said tumor-associated antigen is ~~a self-antigen~~CA125, and wherein the administration of the complex induces cytotoxic T cells reactive with ~~at least one other epitope of~~ the tumor-associated antigen.

106. **(Previously presented)** The method of claim 105, wherein the soluble complex further induces host antibodies reactive with at least one other epitope of the tumor-associated antigen.

107. **(Currently amended)** A method of treating an oncological disease comprising administering to a host a complex formed from a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein said tumor-associated antigen is ~~a self-antigen~~CA125, and wherein the administration of the complex induces host antibodies reactive with at least one other epitope of the tumor-associated antigen.

108. **(Currently amended)** The method of claim 107, wherein the complex induces cytotoxic T cells reactive with ~~at least one other epitope of~~ the tumor-associated antigen.

109. **(Currently amended)** A method of treating an oncological disease comprising administering to a host a complex formed from a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein said tumor-associated antigen is ~~a self-antigen~~CA125, and wherein the administration of the complex induces cytotoxic T cells reactive with ~~at least one other epitope of~~ the tumor-associated antigen.

110. **(Previously presented)** The method of claim 107, wherein the complex induces host antibodies reactive with at least one other epitope of the antigen.

111. **(Previously presented)** The method of claim 30, wherein the antibody or antigen binding fragment thereof is formulated in the complex at a dose of about 2 mg per host.

112. **(Previously presented)** The method of claim 30, wherein the antibody or antigen binding fragment thereof is formulated in the complex at a dose of from about 0.1 μ g to about 200 μ g per kilogram of body weight of the host.

113. **(Previously presented)** The method of any of claims 30, 104, 105, 107, and 109, wherein the antibody is a non-human antibody.

114. **(Previously presented)** The composition of claim 85, wherein the antibody is a non-human antibody.

115.-116. **(Cancelled)**

117. **(Currently amended)** A composition suitable for administration to a host for altering immunogenicity of a tumor-associated antigen comprising a complex of a soluble tumor-associated antigen and an IgG antibody or antigen binding fragment thereof that specifically binds to an epitope of the antigen, wherein said tumor-associated antigen is ~~a self-antigen~~ CA125, and wherein administration of the composition to a host results in a multi-epitopic immune response including production of antibodies reactive with at least one other epitope associated with the tumor-associated antigen.

118. **(Currently amended)** A method of treating an oncological disease comprising stimulating a multi-epitopic immune response to a tumor-associated antigen comprising administering to a host a complex formed from a soluble tumor-associated antigen and an IgG antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein said tumor-associated antigen is ~~a self-antigen~~ CA125, and wherein the administration of the complex induces host antibodies reactive with at least one other epitope of the tumor-associated antigen.

119. **(Currently amended)** A method of treating an oncological disease comprising stimulating a multi-epitopic immune response to a tumor-associated antigen comprising administering to a host a complex formed from a soluble tumor-associated antigen and an IgG antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein said tumor-associated antigen is ~~a self-antigen~~ CA125, and wherein the administration of the complex induces cytotoxic T cells reactive with ~~at least one other epitope of~~ the tumor-associated antigen.

120.-122 **(Cancelled)**

123. **(New)** The method of claim 30, wherein the antibody is produced by the hybridoma having ATCC deposit number PTA-1883.

124. **(New)** The method of claim 104, wherein the antibody is produced by the hybridoma having ATCC deposit number PTA-1883.

125. **(New)** The method of claim 105, wherein the antibody is produced by the hybridoma having ATCC deposit number PTA-1883.

126. **(New)** The method of claim 117, wherein the antibody is produced by the hybridoma having ATCC deposit number PTA-1883.

127. **(New)** The method of claim 118, wherein the antibody is produced by the hybridoma having ATCC deposit number PTA-1883.

128. **(New)** The method of claim 119, wherein the antibody is produced by the hybridoma having ATCC deposit number PTA-1883.